Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

Merck MRK has reached a significant support level, making it an attractive option for investors from a technical standpoint. Since early June, the stock has broken through its 50-day simple moving ...

Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...

Jefferies analyst Akash Tewari remains bullish on Merck, maintaining a Buy rating and a $138 price target. The firm’s ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best and Cheap Stocks to Buy Now. On June 18, Akash Tewari, an analyst from ...

Merck MRK announced that the phase III HYPERION study evaluating its pulmonary arterial hypertension (“PAH”) drug, Winrevair ...

Keytruda (pembrolizumab) is approved for head and neck squamous cell carcinoma as a perioperative treatment regimen.

In this video, Susana M. Campos, MD, MPH, discusses results from the final analysis of the phase 3 A18 study in advanced cervical cancer, presented at ASCO Annual Meeting.The ...

In this video, Susana M. Campos, MD, MPH, discusses results from a single-arm phase 2 study of the concurrent treatment of vulvar cancer with chemoradiation and pembrolizumab.Patients who underwent ...

Historic changes are afoot for pharma as China gains ground on U.S. production. The pharma industry is projected to see ...

ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost ...